# EDGAR Filing Document

**Accession Number:** 0001931891
**File Stem:** 0001931382-26-000007
**Filing Date:** 2026-5
**Character Count:** 8818
**Document Hash:** 386560bfd2d10eeb0fdf8f518fb4f232
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001931382-26-000007.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001931382-26-000007

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260511

**FILED AS OF DATE**: 20260528

**DATE AS OF CHANGE**: 20260528

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** GC Corp.
- **CENTRAL INDEX KEY:** 0001931382

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** M5
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42179
- **FILM NUMBER:** 261036857

**BUSINESS ADDRESS:**
- **STREET 1:** 107 IHYEON-RO,30BEON-GIL
- **STREET 2:** GILHEUNG-GU, YONGIN-SI
- **CITY:** GYEONGGI-DO
- **STATE:** M5
- **ZIP:** 16924
- **BUSINESS PHONE:** 82-31-260-9300

**MAIL ADDRESS:**
- **STREET 1:** 107 IHYEON-RO,30BEON-GIL
- **STREET 2:** GILHEUNG-GU, YONGIN-SI
- **CITY:** GYEONGGI-DO
- **STATE:** M5
- **ZIP:** 16924

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Green Cross Holdings Corp
- **DATE OF NAME CHANGE:** 20220526
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** GC Cell Corp
- **CENTRAL INDEX KEY:** 0001931891

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** M5
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42179
- **FILM NUMBER:** 261036856

**BUSINESS ADDRESS:**
- **STREET 1:** 107 IHYEON-RO, 30BEON-GIL
- **STREET 2:** GILHEUNG-GU, YONGIN-SI
- **CITY:** GYEONGGI-DO
- **STATE:** M5
- **ZIP:** 16924
- **BUSINESS PHONE:** 82-31-260-9300

**MAIL ADDRESS:**
- **STREET 1:** 107 IHYEON-RO, 30BEON-GIL
- **STREET 2:** GILHEUNG-GU, YONGIN-SI
- **CITY:** GYEONGGI-DO
- **STATE:** M5
- **ZIP:** 16924
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Artiva Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001817241
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863614316
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 5505 MOREHOUSE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 267-4467

**MAIL ADDRESS:**
- **STREET 1:** 5505 MOREHOUSE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>GC Corp.<br><sub>(Last) (First) (Middle)</sub><br>107 IHYEON-RO,30BEON-GIL<br>GILHEUNG-GU<br><sub>(Street)</sub><br>YONGIN-SI, KOREA, REPUBLIC OF 16924<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Artiva Biotherapeutics, Inc. [ ARTV ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>GC Cell Corp<br><sub>(Last) (First) (Middle)</sub><br>107 IHYEON-RO, 30BEON-GI<br>GIHEUNG-GU,<br><sub>(Street)</sub><br>YONGIN-SI, KOREA, REPUBLIC OF 16924<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Artiva Biotherapeutics, Inc. [ ARTV ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-11 |  | P |  | 1085069 | A | $11.52 | 4391969 | D<sup>(1)</sup> |  |
| Common Stock | 2026-05-11 |  | P |  | 347222 | A | $11.52 | 1607734 | I | By GC Cell Corporation<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by GC Corp., except to the extent of any pecuniary interest therein.

(2) The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein.

**Signature:** GC Corp. By: /s/ Yong-Jun Huh, Chief Executive Officer  
**Date:** 2026-05-28

**Signature:** GC Cell Corporation By: /s/ Jaiwang Kim, Chief Executive Officer  
**Date:** 2026-05-28

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**